Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
BPC2.5
BPC-157 – Forschung
Überwiegend Mechanismus / Beobachtung
28 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu BPC-157 sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus mittelwertigen Studien, veröffentlicht 1997–2026 mit einer typischen Studiengröße von 30 Teilnehmenden.
Basierend auf 28 Studien · 352 Teilnehmende insgesamt
Konfidenz
Geringe Konfidenz
Nach Outcome
Tendon, ligament & soft-tissue healingHeilung von Sehnen, Bändern, Muskeln und Darm nur im Tierversuch gezeigt; keine nachgewiesene Wirksamkeit beim Menschen und ein theoretisches Risiko einer Tumorwachstumsförderung. · Nicht etabliert (keine Humanstudien)
Überwiegend Mechanismus / Beobachtung10 Studien
Digestive health
Überwiegend Mechanismus / Beobachtung3 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung3 Studien
Wound & ulcer healing
Zu wenige bewertete Studien2 Studien
Pain & analgesia
Zu wenige bewertete Studien1 Studie
Aktives Forschungsgebiet
21 Studien in den letzten 5 Jahren
199720112026
1Systematische Übersichtn=30 · small study2026
Addressing these biopharmaceutical gaps is a prerequisite for any meaningful clinical program.
Available clinical data derive from fewer than 30 subjects across three uncontrolled pilot studies, none of which employed standardized pharmaceutical preparations.
Conclusions : BPC-157 presents a compelling but pharmaceutically underdeveloped profile.
The primary barrier to clinical translation is not the absence of biological activity, but the absence of fundamental pharmaceutical science: characterized formulations, validated pharmacokinetics, and a coherent drug development strategy.
This systematic-review examined the effects of BPC-157.
Sikiric P, Barisic I, Udovicic M, Lovric Bencic M, Balenovic D, Strinic D, Zivanovic Posilovic G, Uzun S, Vranes H, Krezic I, Lozic M, Stambolija V, Premuzic Mestrovic I, Beketic Oreskovic L, Oreskovic I, Strbe S, Sikiric S, Tomic L, Kordic M, Tvrdeic A, Seiwerth S, Boban Blagaic A, Skrtic A. · Pharmaceuticals (Basel, Switzerland) (2026)
Systematic review examining BPC-157 efficacy
Published in Pharmaceuticals (Basel, Switzerland) (2026)
Further research warranted to confirm findings
3Systematische Übersicht2026
Nevertheless, reliance on preclinical models necessitates further clinical validation.
Sikiric P, Barisic I, Udovicic M, Lovric Bencic M, Balenovic D, Strinic D, Posilovic GZ, Uzun S, Vranes H, Krezic I, Lozic M, Stambolija V, Premuzic Mestrovic I, Oreskovic LB, Kalogjera L, Strbe S, Sikiric S, Tomic L, Stupnisek M, Kordic M, Tvrdeic A, Seiwerth S, Boban Blagaic A, Skrtic A. · Pharmaceuticals (Basel, Switzerland) (2026)
As a comparison from a cytoprotective (partial vs. full) standpoint, conventional agents-anticoagulants, antiplatelet drugs, and fibrinolytics-provide only partial protection by targeting isolated components of hemostasis.
Nevertheless, reliance on preclinical models necessitates further clinical validation.
Further clinical studies will strengthen cytoprotective therapy and, particularly, BPC 157 in complex musculoskeletal and junctional injuries.
Matek D, Matek I, Japjec M, Matek M, Prenc J, Staresinic B, Staresinic E, Prtoric A, Sikiric S, Beketic Oreskovic L, Oreskovic I, Strbe S, Kordic M, Tvrdeic A, Seiwerth S, Sikiric P, Boban Blagaic A, Skrtic A, Bojanic I, Dobric I, Staresinic M. · Pharmaceuticals (Basel, Switzerland) (2026)
The estimated key was the success of injury recovery amid each agent's direct exogenous administration, alone or with a carrier, locally or systemically, without reliance on complex scaffolds, carriers, or tissue-engineering constructs.
Contrarily, proposed as a cytoprotection mediator, BPC 157 acts alone with a full cytoprotection range, given systemically or locally.
Moreover, without any carrier, BPC 157 acts alone, combining beneficial effects on tendon, ligament, and muscle injuries with osteotendinous, myotendinous, and muscle-to-bone healing.
This systematic-review examined the effects of BPC-157.
Matek D, Matek I, Japjec M, Matek M, Prenc J, Staresinic B, Staresinic E, Prtoric A, Sikiric S, Beketic Oreskovic L, Oreskovic I, Strbe S, Kordic M, Tvrdeic A, Seiwerth S, Sikiric P, Boban Blagaic A, Skrtic A, Bojanic I, Dobric I, Staresinic M. · Pharmaceuticals (Basel, Switzerland) (2026)
Systematic review examining BPC-157 efficacy
Published in Pharmaceuticals (Basel, Switzerland) (2026)
Further research warranted to confirm findings
6Systematische Übersicht2026
Peptide therapeutics, therefore, represent a developing research domain whose relevance to thyroid care remains to be established through rigorous investigation.
Mazza AD. · Integrative medicine (Encinitas, Calif.) (2026)
Safety profiles vary across peptide classes, and clinical use remains largely investigational in the context of thyroid disease.
This review presents potential biologic pathways linking peptide activity to immune and metabolic aspects of thyroid disorders, as well as regulatory and ethical considerations surrounding emerging peptide applications.
Substantial evidence gaps persist, and well-designed thyroid-focused clinical trials are needed to clarify safety, efficacy, and appropriate clinical roles.
7Systematische Übersichtn=293 · medium study2026
Thus, to confirm the hypothesis, these BPC 157 conditional, not constitutive effects, in rodent models or in vitro systems (HEK293 cells), mandate expansion of now limited clinical data and mechanisms in human investigated as a translational cytoprotective strategy for complex arrhythmias.
Sikiric P, Barisic I, Udovicic M, Lovric Bencic M, Balenovic D, Strinic D, Zivanovic Posilovic G, Uzun S, Vranes H, Krezic I, Lozic M, Stambolija V, Premuzic Mestrovic I, Beketic Oreskovic L, Oreskovic I, Strbe S, Sikiric S, Tomic L, Kordic M, Tvrdeic A, Seiwerth S, Boban Blagaic A, Skrtic A. · Pharmaceuticals (Basel, Switzerland) (2026)
In vivo, this was across models of hypo-/hyperkalemia, hypermagnesemia, ischemia-reperfusion, myocardial infarction, drug-induced arrhythmias (including local anesthetics), and vascular occlusion.
BPC 157 restores sinus rhythm, normalizes P/QRS/QT intervals, prevents AV block, suppresses VT, attenuates ST-segment changes, and stabilizes heart rate, even when insults are advanced.
Thus, to confirm the hypothesis, these BPC 157 conditional, not constitutive effects, in rodent models or in vitro systems (HEK293 cells), mandate expansion of now limited clinical data and mechanisms in human investigated as a translational cytoprotective strategy for complex arrhythmias.
BPC-157 remains a promising candidate for regenerative medicine, yet comprehensive evaluation is required before clinical translation can be recommended.
Yuan C, Demers A, Silva-Ortiz V, Hasoon JJ, Lee W, Dave K, Amirdelfan K, Burke HW, Christo PJ, Robinson CL. · International journal of molecular sciences (2026)
Studies also report reduced inflammatory cytokine activity, improved microvascular integrity, and beneficial effects on pain modulation through peripheral and dopaminergic mechanisms.
Although animal data indicate favorable safety and pharmacokinetics, human research remains limited to small pilot studies investigating musculoskeletal pain, interstitial cystitis, and intravenous administration, all suggesting potential therapeutic value without reported major adverse effects.
However, inconsistent preparation standards, limited clinical validation, and regulatory restrictions underscore the need for rigorous controlled trials.
Taken together, these findings advance cytoprotection as a unifying therapeutic paradigm, with BPC 157 emerging as its first exemplar, and encourage further translational research toward clinical application.
Masnec S, Kokot A, Kralj T, Zlatar M, Loncaric K, Sablic M, Kalauz M, Beslic I, Oroz K, Mrvelj B, Beketic Oreskovic L, Oreskovic I, Strbe S, Staresinic B, Slivsek G, Boban Blagaic A, Seiwerth S, Skrtic A, Sikiric P. · Pharmaceuticals (Basel, Switzerland) (2025)
The cornea's "angiogenic privilege," preserved during healing and tendon recovery together, provides strong proof of concept.
Furthermore, mapping standard therapeutic agents used for corneal ulcers, neovascularization, or glaucoma onto this triad, and linking them with tendon healing, reveals both shared pathways and inconsistencies across existing drug classes.
Taken together, these findings advance cytoprotection as a unifying therapeutic paradigm, with BPC 157 emerging as its first exemplar, and encourage further translational research toward clinical application.
Likewise, not only in ACS/IAH resolving, but also in other occlusion/occlusion-like syndromes, this "bypassing key" could be an effect of the essential endothelial cytoprotective capacity of BPC 157 and a particular modulatory effect on the NO-system, and a rescuing impact on vasomotor tone.
Sikiric P, Seiwerth S, Skrtic A, Staresinic M, Strbe S, Vuksic A, Sikiric S, Bekic D, Penovic T, Drazenovic D, Becejac T, Tepes M, Madzar Z, Novosel L, Beketic Oreskovic L, Oreskovic I, Stupnisek M, Boban Blagaic A, Dobric I. · Pharmaceuticals (Basel, Switzerland) (2025)
BPC 157 therapy rapidly activates collateral bypassing pathways, and, in ACS and IAH, and later, in reperfusion, there is a "bypassing key" (i.e., azygos vein direct blood flow delivery).
Likewise, not only in ACS/IAH resolving, but also in other occlusion/occlusion-like syndromes, this "bypassing key" could be an effect of the essential endothelial cytoprotective capacity of BPC 157 and a particular modulatory effect on the NO-system, and a rescuing impact on vasomotor tone.
We also present recent interest in BPC 157 as reflected in a number of patent applications and granted patents.
Józwiak M, Bauer M, Kamysz W, Kleczkowska P. · Pharmaceuticals (Basel, Switzerland) (2025)
However, it has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans.
In this review, we summarize information on the biological activities of BPC 157, with particular reference to its mechanism of action and probable toxicity.
This generated the attention of experts, as BPC 157 has been offered for sale on many websites.
Thus, BPC 157 therapy means targeting angiogenesis and NO's cytotoxic and damaging actions but maintaining, promoting, or recovering their essential protective functions.
Sikiric P, Seiwerth S, Skrtic A, Staresinic M, Strbe S, Vuksic A, Sikiric S, Bekic D, Soldo D, Grizelj B, Novosel L, Beketic Oreskovic L, Oreskovic I, Stupnisek M, Boban Blagaic A, Dobric I. · Pharmaceuticals (Basel, Switzerland) (2025)
BPC 157 resolved cornea transparency maintenance, cornea healing "angiogenic privilege" (vs. angiogenesis/neovascularization/tumorigenesis), and it does not produce corneal neovascularization but rather opposes it.
Per Folkman's concept, it demonstrates an anti-tumor effect in vivo and in vitro.
BPC 157 exhibits a distinctive effect on the NO-level (increase vs. decrease), always combined with the counteraction of free radical formation, and, in mice and rats, BPC 157 therapy counteracts Parkinson's disease-like and Alzheimer's disease-like disturbances.
This review highlights that given the robust preclinical evidence and high public interest, there is a critical need for well-designed human trials to assess the safety, efficacy, and clinical utility of BPC-157 in musculoskeletal medicine.
McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. · Current reviews in musculoskeletal medicine (2025)
BPC-157 demonstrates robust regenerative and cytoprotective effects in preclinical studies, positioning it as a potentially valuable tool in musculoskeletal medicine.
Despite its growing popularity among athletes and its wide availability through non-regulated sources, there is minimal human data available.
Until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and its use approached with caution.
Finally, there is nerve-muscle relation in various muscle disturbance counteractions, and nerve-nerve relation in various encephalopathies counteraction, which is also exemplified specifically by the BPC 157 therapy application.
Sikiric P, Boban Blagaic A, Strbe S, Beketic Oreskovic L, Oreskovic I, Sikiric S, Staresinic M, Sever M, Kokot A, Jurjevic I, Matek D, Coric L, Krezic I, Tvrdeic A, Luetic K, Batelja Vuletic L, Pavic P, Mestrovic T, Sjekavica I, Skrtic A, Seiwerth S. · Pharmaceuticals (Basel, Switzerland) (2024)
This specifically includes counteraction of those disturbances related to their receptors, both blockade and over-activity, destruction, depletion, tolerance, sensitization, and channel disturbances counteraction.
Furthermore, close BPC 157/NO-system relations with the gasotransmitters crossing the cell membrane and acting directly on molecules inside the cell may envisage particular interactions with receptors on the plasma membrane of their target cells.
This systematic-review examined the effects of BPC-157.
Sikiric P, Sever M, Krezic I, Vranes H, Kalogjera L, Smoday IM, Vukovic V, Oroz K, Coric L, Skoro M, Kavelj I, Zubcic S, Sikiric S, Beketic Oreskovic L, Oreskovic I, Blagaic V, Brcic K, Strbe S, Staresinic M, Boban Blagaic A, Skrtic A, Seiwerth S. · Inflammopharmacology (2024)
These overwhelm current clinical evidence (i.e., ulcerative colitis, phase II, no side effects, and no lethal dose (LD1) in toxicology studies), as BPC 157 therapy effectively combined various tissue healing and lesions counteraction.
This may be a particular reconnection of the parts of the gastrointestinal tract to re-establish adequate integrity depending on the tissue involved, given that both various intestinal anastomoses and various fistulas (intestinal and skin were accordingly healed simultaneously as the fistulas disappeared) were all healed.
Bajramagic S, Sever M, Rasic F, Staresinic M, Skrtic A, Beketic Oreskovic L, Oreskovic I, Strbe S, Loga Zec S, Hrabar J, Coric L, Prenc M, Blagaic V, Brcic K, Boban Blagaic A, Seiwerth S, Sikiric P. · Pharmaceuticals (Basel, Switzerland) (2024)
In principle, the healing of quite distinctive anastomoses itself speaks for applied BPC 157 therapy, in particular, as a way in which the therapy of anastomoses can be successfully approached and carried out.
Published in Pharmaceuticals (Basel, Switzerland) (2024)
BPC 157 promotes the ex vivo outgrowth of tendon fibroblasts from tendon explants, cell survival under stress, and the in vitro migration of tendon fibroblasts, which is likely mediated by the activation of the FAK-paxillin pathway.
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. · J Appl Physiol (1985) (2011)
In-vitro / ex-vivo study using rat Achilles-tendon explants and cultured tendon fibroblasts
BPC 157 accelerated fibroblast outgrowth from explants and increased cell survival under H2O2 oxidative stress
Dose-dependently increased fibroblast migration and spreading and induced F-actin formation
A complex protective interaction with both alpha-adrenergic (eg, catecholamine release) and dopaminergic (central) systems could be suggested for both intragastric and intraperitoneal BPC 157 administration.